Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies

Circulation

Volumn 133, Issue 3, 2016, Pages 256-264

  Colantonio, Lisandro D ^a   Bittner, Vera ^b   Reynolds, Kristi ^d   Levitan, Emily B ^a   Rosenson, Robert S ^e   Banach, MacIej ^f   Kent, Shia T ^a   Derose, Stephen F ^d   Zhou, Hui ^d   Safford, Monika M ^c   Muntner, Paul ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Division of Cardiovascular Disease   (United States)

^c University of Alabama at Birmingham   (United States)

^d KAISER PERMANENTE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Coronary disease; epidemiology; follow up studies; lipids

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; BLOOD; CORONARY ARTERY DISEASE; UNITED STATES;

CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LIPOPROTEINS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; OBSERVATIONAL STUDIES AS TOPIC; RISK FACTORS; SOUTHEASTERN UNITED STATES; TRIGLYCERIDES;

EID: 84955692142     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.011646     Document Type: Article

References (34)

1. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 285 2486 2497
2. Mann D, Reynolds K, Smith D, Muntner P, Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 2008 42 1208 1215. doi: 10.1345/aph.1L181
3. Muntner P, Levitan EB, Brown TM, Sharma P, Zhao H, Bittner V, Glasser S, Kilgore M, Yun H, Woolley JM, Farkouh ME, Rosenson RS, Trends in the prevalence, awareness, treatment and control of high low density lipoprotein-cholesterol among United States adults from 1999-2000 through 2009-2010. Am J Cardiol 2013 112 664 670. doi: 10.1016/j.amjcard.2013.04.041
4. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P, CHD Risk Prediction Group Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001 286 180 187
5. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB, General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008 117 743 753. doi: 10.1161/CIRCULATIONAHA.107.699579
6. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF, American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014 129 suppl 2 S49 S73. doi: 10.1161/01.cir.0000437741.48606.98
7. Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, Graham A, Moy CS, Howard G, The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology 2005 25 135 143. doi: 10.1159/000086678
8. Safford MM, Brown TM, Muntner PM, Durant RW, Glasser S, Halanych JH, Shikany JM, Prineas RJ, Samdarshi T, Bittner VA, Lewis CE, Gamboa C, Cushman M, Howard V, Howard G, REGARDS Investigators Association of race and sex with risk of incident acute coronary heart disease events. JAMA 2012 308 1768 1774. doi: 10.1001/jama.2012.14306
9. Koebnick C, Langer-Gould AM, Gould MK, Chao CR, Iyer RL, Smith N, Chen W, Jacobsen SJ, Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J 2012 16 37 41
10. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives: the ARIC investigators. Am J Epidemiol 1989 129 687 702
11. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997 20 1183 1197
12. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) A new equation to estimate glomerular filtration rate. Ann Intern Med 2009 150 604 612
13. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ, Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003 41 47 55
14. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013 3 1 150
15. Friedewald WT, Levy RI, Fredrickson DS, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 18 499 502
16. Luepker RV, Apple FS, Christenson RH, Crow RS, Fortmann SP, Goff D, Goldberg RJ, Hand MM, Jaffe AS, Julian DG, Levy D, Manolio T, Mendis S, Mensah G, Pajak A, Prineas RJ, Reddy KS, Roger VL, Rosamond WD, Shahar E, Sharrett AR, Sorlie P, Tunstall-Pedoe H, AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation 2003 108 2543 2549. doi: 10.1161/01.CIR.0000100560.46946.EA
17. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR, Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009 338 b2393
18. White IR, Royston P, Wood AM, Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 2011 30 377 399. doi: 10.1002/sim.4067
19. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM, SCORE Project Group Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003 24 987 1003
20. Dawber TR, Kannel WB, Lyell LP, An approach to longitudinal studies in a community: the Framingham study. Ann N Y Acad Sci 1963 107 539 556
21. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE, Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997 96 2520 2525
22. Lerner DJ, Kannel WB, Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986 111 383 390
23. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S, INTERHEART Study Investigators Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008 372 224 233. doi: 10.1016/S0140-6736(08)61076-4
24. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J, Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009 302 1993 2000
25. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344 1383 1389
26. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 7 22
27. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003 361 2005 2016
28. Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A, Efficacy and safety of LDL-lowering therapy among men and women: meta-Analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015 385 1397 1405
29. Law MR, Wald NJ, Rudnicka AR, Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-Analysis. BMJ 2003 326 1423. doi: 10.1136/bmj.326.7404.1423
30. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 333 1301 1307. doi: 10.1056/NEJM199511163332001
31. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S, Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011 CD004816. doi: 10.1002/14651858.CD004816.pub4
32. Talwalkar PG, Sreenivas CG, Gulati A, Baxi H, Journey in guidelines for lipid management: from Adult Treatment Panel (ATP)-I to ATP-III and what to expect in ATP-IV. Indian J Endocrinol Metab 2013 17 628 635. doi: 10.4103/2230-8210.113753
33. Aronow HD, Dutro MP, Kuznik A, Cwengros J, Prevalence of cardiovascular comorbidities and utilization of evidence-based treatment strategies among statin users in a Medicare and commercial health plan. Curr Med Res Opin 2009 25 205 213. doi: 10.1185/03007990802611828
34. Cole SR, Platt RW, Schisterman EF, Chu H, Westreich D, Richardson D, Poole C, Illustrating bias due to conditioning on a collider. Int J Epidemiol 2010 39 417 420. doi: 10.1093/ije/dyp334